scholarly journals Federal Workplace Charging Program Guide

2020 ◽  
Keyword(s):  
Charging Program ◽  
Federal Workplace ◽  
Workplace Charging

scholarly journals Federal Workplace Charging Program Guide

2020 ◽  
Author(s):  
Cabell Hodge ◽  
Jesse Bennett
Keyword(s):  
Charging Program ◽  
Federal Workplace ◽  
Workplace Charging

An Assessment of a Drastically Changed Federal Workplace in the United States

2003 ◽  
Vol 26 (10-11) ◽  
pp. 1097-1102
Author(s):  
Ray C. Oman ◽  
Ronald L. Gabriel ◽  
Jacqueline J. Garrett ◽  
Kenneth B. Malmberg
Keyword(s):  
United States ◽  
The United States ◽  
Federal Workplace

scholarly journals Urinary Pharmacokinetic Profile of Cannabinoids Following Administration of Vaporized and Oral Cannabidiol and Vaporized CBD-Dominant Cannabis

2019 ◽  
Vol 44 (2) ◽  
pp. 109-125 ◽  
Author(s):  
Tory R Spindle ◽  
Edward J Cone ◽  
David Kuntz ◽  
John M Mitchell ◽  
George E Bigelow ◽  
...  
Keyword(s):  
Drug Testing ◽  
Drug Effects ◽  
Pharmacokinetic Profile ◽  
Chemical Constituent ◽  
Positive Urine ◽  
Urine Drug ◽  
Confirmatory Tests ◽  
Federal Workplace ◽  
The Impact ◽  
Urine Specimens

Abstract Cannabis products in which cannabidiol (CBD) is the primary chemical constituent (CBD-dominant) are increasingly popular and widely available. The impact of CBD exposure on urine drug testing has not been well studied. This study characterized the urinary pharmacokinetic profile of 100-mg oral and vaporized CBD, vaporized CBD-dominant cannabis (100-mg CBD; 3.7-mg ∆9-THC) and placebo in healthy adults (n = 6) using a within-subjects crossover design. Urine specimens were collected before and for 5 days after drug administration. Immunoassay (IA) screening (cutoffs of 20, 50 and 100 ng/mL) and LC–MS-MS confirmatory tests (cutoff of 15 ng/mL) for 11-nor-9-carboxy-∆9-tetrahydrocannabinol (∆9-THCCOOH) were performed; urine was also analyzed for CBD and other cannabinoids. Urinary concentrations of CBD were higher after oral (mean Cmax: 776 ng/mL) versus vaporized CBD (mean Cmax: 261 ng/mL). CBD concentrations peaked 5 h after oral CBD ingestion and within 1 h after inhalation of vaporized CBD. After pure CBD administration, only 1 out of 218 urine specimens screened positive for ∆9-THCCOOH (20-ng/mL IA cutoff) and no specimens exceeded the 15-ng/mL confirmatory cutoff. After inhalation of CBD-dominant cannabis vapor, nine samples screened positive at the 20-ng/mL IA cutoff, and two of those samples screened positive at the 50-ng/mL IA cutoff. Four samples that screened positive (two at 20 ng/mL and two at 50 ng/mL) confirmed positive with concentrations of ∆9-THCCOOH exceeding 15 ng/mL. These data indicate that acute dosing of pure CBD will not result in a positive urine drug test using current federal workplace drug testing guidelines (50-ng/mL IA cutoff with 15-ng/mL confirmatory cutoff). However, CBD products that also contain ∆9-THC may produce positive urine results for ∆9-THCCOOH. Accurate labeling and regulation of ∆9-THC content in CBD/hemp products are needed to prevent unexpected positive drug tests and unintended drug effects.

Monitoring the charging program and the mass of charge materials fed to the blast furnace

Metallurgist ◽  
1977 ◽  
Vol 21 (10) ◽  
pp. 659-661
Author(s):  
Yu. A. Reznikov ◽  
V. L. Oleshko ◽  
S. V. Korshikov ◽  
N. I. Valov
Keyword(s):  
Blast Furnace ◽  
Charge Materials ◽  
Charging Program
Sign in / Sign up

Export Citation Format

Share Document